(Total Views: 847)
Posted On: 09/07/2020 5:40:17 PM
Post# of 154089
Re: chazzledazzle #54571
Chazzle,
The market for leronlimab is either, IMO so high as to be essentially incalculable or just ridiculous to the point of obscenity.
Take half of the indications on the Ohm20 list and assume that leronlimab would have even 25% of the market for direct costs, and the valuations at 5x revenues soon become laughable.
The poster Black-ops on Ihub, who appears very legitimate, offers valuations dwarfing any existing BP. I do not believe that Drs Lalezari and Patterson, and the ramifications of their analyses, are off-base.
Just one more reason that I just laughed and bough my last 100 as SP was under 3 a few days back.
It is laughable how, IMO, how de-risked this OTC company run by the mad scrabble group of Leronlimab Underdogs is and how the larger markets and world still don’t get it.
The “secret” is being screamed from the rooftops and still not being heard.
Soon enough
The market for leronlimab is either, IMO so high as to be essentially incalculable or just ridiculous to the point of obscenity.
Take half of the indications on the Ohm20 list and assume that leronlimab would have even 25% of the market for direct costs, and the valuations at 5x revenues soon become laughable.
The poster Black-ops on Ihub, who appears very legitimate, offers valuations dwarfing any existing BP. I do not believe that Drs Lalezari and Patterson, and the ramifications of their analyses, are off-base.
Just one more reason that I just laughed and bough my last 100 as SP was under 3 a few days back.
It is laughable how, IMO, how de-risked this OTC company run by the mad scrabble group of Leronlimab Underdogs is and how the larger markets and world still don’t get it.
The “secret” is being screamed from the rooftops and still not being heard.
Soon enough
(15)
(0)
